Health Catalyst Capital
VC Fund
New York, United States
Health Catalyst Capital is a VC fund in New York focused on Health Care and Medical. Health Catalyst Capital Management is a venture capital fund investing in high growth US- based Healthcare IT businesses focused in a few key themes, each with potential to achieve $1 billion enterprise value in new or disrupted markets globally.
- Total investments:
- 32
- Last investment:
- Lead investor:
- 41%
- Fund size:
- $4M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Health Catalyst Capital invests in
Stages Health Catalyst Capital invests in
Countries Health Catalyst Capital invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $3.9M–$22M
- Series B
- $11M–$52M
- Venture - Series Unknown
- $30M–$30M
Investment Focus
Industry
- Health Care 18 (56%)
- Medical 5 (16%)
- Software 5 (16%)
- Wellness 4 (13%)
- Mobile Apps 4 (13%)
Stage
- Series B 8 (25%)
- Venture - Series Unknown 8 (25%)
- Series A 6 (19%)
- Seed 2 (6%)
- Series D 2 (6%)
Country
- United States 17 (53%)
- Singapore 1 (3%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Dan Ross
Partner
|
Partner | Total investments: 1 | Find email | |
Bryan Carey
Operating Partner
|
Operating Partner | Total investments: 0 | Find email | |
Charles Boorady
Managing Partner
|
Managing Partner | Total investments: 16 | Find email | |
Nikhil Hanmantgad
Principal
|
Principal | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Glooko
|
Glooko is the universal diabetes platform that provides insights to improve outcomes for people with diabetes (PWDs) and their care teams. Glooko connects to the world’s most popular diabetes devices, major fitness and activity trackers and supplies personalized, timely patient information such as glucose level, food, insulin, medications, bloodpressure, diet and weight data. Trusted by the world’s leaders in diabetes care, we are in over 7,000 clinical locations and used by over 1.5 million PWDs in 23 countries across 15 languages. Learn more by visiting www.glooko.com. | $100M / Series F / Oct 10, 2024 | |
|
Glooko
|
Glooko is the universal diabetes platform that provides insights to improve outcomes for people with diabetes (PWDs) and their care teams. Glooko connects to the world’s most popular diabetes devices, major fitness and activity trackers and supplies personalized, timely patient information such as glucose level, food, insulin, medications, bloodpressure, diet and weight data. Trusted by the world’s leaders in diabetes care, we are in over 7,000 clinical locations and used by over 1.5 million PWDs in 23 countries across 15 languages. Learn more by visiting www.glooko.com. | $100M / Private Equity / Oct 10, 2024 | |
Vivante Health
|
Since 2016, Vivante Health has been revolutionizing digestive health and wellness, one person at a time. Our category-defining digital health solutions provide personalized, comprehensive care for people with digestive conditions. Our all-in-one digestive health program GIThrive® combines clinically-backed interactive tech, targeted nutrition, and24/7 personal support to improve digestive disease outcomes, and reduce the cost of care. GIThrive is used by large employers and health plans to reduce the costs of chronic disease, improve employee health, and workplace absenteeism. | $31M / Series B / Sep 20, 2023 | |
Cylinder
|
Founded in 2021 and offered as an employer benefit, Cylinder (formerly Vivante Health) delivers personalized, clinician-backed care to those suffering from digestive issues through its virtual health platform. Cylinder’s tech-forward, human-first program connects members to the right level of support at the right time through an easy interface,bringing the healthcare ecosystem together to align around member needs. Cylinder’s dedicated care teams help members proactively address their gut health from every angle – decreasing costs, reducing absenteeism, and improving their quality of life, at scale. Cylinder’s vision is to create a world where people receive convenient, personalized, and affordable access to the quality digestive healthcare they need to improve their overall health. Learn more at cylinderhealth.com. | $31M / Series B / Sep 20, 2023 | |
Clearsense
|
Clearsense is a software company that provides healthcare analytics and data management solutions for patients and organizations. Its platform converts data into a single source of truth to accelerate data maturity, optimize analytics tools, improve decision quality, and unlock meaningful outcomes.The 1Clearsense Data Management Platform is asecure and scalable platform that ingests, aggregates, and manages data so that users can consume and use it to make informed real-time decisions. Clearsense's data-first approach eliminates assumptions and replaces them with a single source of trusted data by leveraging data from disparate systems across the organization. | $50M / Series D / Jan 31, 2023 | |
ReferWell
|
ReferWell connects providers into Virtually Integrated Networks that optimize transitions of care. We help you drive the patient journey through the last mile with complete visibility into all interactions—so providers and payers can close the loop efficiently.With our system, you’ll direct patients toward the highest-quality providers, increasepatient compliance, reduce leakage and close more care gaps. Clients raise revenue by increasing keepage, improving STAR ratings and getting more members’ HCC coding updated. Our comprehensive suite of services connects to all your EMRs for streamlined referrals, point-of-care appointment scheduling and care team support, including provider directory management, eConsult and telehealth capabilities. | Series B / Jan 10, 2023 | |
Holmusk
|
Holmusk is developing a Real-World Evidence platform in behavioral health and chronic diseases to expand data-driven, evidence-based care for people managing behavioral health conditions. It works by bringing together specialty behavioral health data and Holmusk’s novel analytics platform to deliver evidence-based insight that can be used to maketreatment decisions, as well as the commercialization of new drugs.Holmusk was founded in 2015 and is based in Singapore, Malaysia, and the USA. | $45M / Series B / Jan 09, 2023 | |
|
Holmusk
|
Holmusk is developing a Real-World Evidence platform in behavioral health and chronic diseases to expand data-driven, evidence-based care for people managing behavioral health conditions. It works by bringing together specialty behavioral health data and Holmusk’s novel analytics platform to deliver evidence-based insight that can be used to maketreatment decisions, as well as the commercialization of new drugs.Holmusk was founded in 2015 and is based in Singapore, Malaysia, and the USA. | Venture - Series Unknown / Dec 06, 2021 | |
PierianDx
|
PierianDx is catalyzing global adoption of genomic sequencing in healthcare by empowering physicians in the laboratory and clinic to more effectively diagnose and treat patients with cancer and other complex diseases. PierianDx’s industry-leading genomic SaaS solutions, CAP and CLIA accredited laboratory, and shared knowledgebase are used by healthsystems, cancer centers and commercial laboratories worldwide driving the most integrated approach across the clinical care spectrum. From genomic sequencing and biomedical informatics in the laboratory to reporting and decision support at the patient’s bedside, PierianDx has rapidly become the trusted source of ‘wisdom’ in every advanced genomic report. | $30M / Venture - Series Unknown / Nov 02, 2021 | |
Click Therapeutics
|
Click Therapeutics develops and commercializes software as medical treatments for people with unmet medical needs. Through cognitive and neurobehavioral mechanisms, Click’s Digital Therapeutics™ enable change within individuals, and are designed to be used independently or in conjunction with biomedical treatments. The Clickometrics® adaptive datascience platform continuously personalizes user experience to optimize engagement and outcomes. Following a groundbreaking clinical trial, Click’s industry-leading smoking cessation program is available nationwide through a wide variety of payers, providers, and employers. Click’s lead prescription program is entering into a multi-center, randomized, controlled, parallel-group, phase III FDA registration trial for the treatment of Major Depressive Disorder in adults. | $52M / Series B / Oct 22, 2021 | |
| See all 32 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Health Catalyst Capital invest in?
Health Catalyst Capital invests primarily in Health Care, Medical and Software startups, most often at Series B and Venture - Series Unknown stage. Most of the 32 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Health Catalyst Capital's check size?
Health Catalyst Capital typically joins rounds of $3.9M–$22M at Series A, $11M–$52M at Series B and $30M–$30M at Venture - Series Unknown. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Health Catalyst Capital participates in.
How do I contact Health Catalyst Capital?
Public channels for Health Catalyst Capital include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Health Catalyst Capital?
The team at Health Catalyst Capital includes Dan Ross (Partner), Bryan Carey (Operating Partner) and Charles Boorady (Managing Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
